Skip to content
All resources

Epithalon

What Is Epitalon? Structure, Origin, Evidence and Regulatory Status

OS

By

· 11 min read

A summary of published research, with citations. It states no amount, schedule or route, and makes no claim about what this compound does in a person. Supplied for laboratory research use only.

On this page · 6 sections
  1. What is Epitalon made of?
  2. How is Epitalon thought to work?
  3. What has Epitalon been studied for?
  4. Is Epitalon approved anywhere?
  5. What is Epitalon commonly confused with?
  6. Frequently asked questions

Epitalon, also spelled Epithalon and known by its sequence AEDG, is a synthetic four-residue peptide, Ala-Glu-Asp-Gly. It was designed in St Petersburg by Vladimir Khavinson's group as a defined counterpart to epithalamin, a polypeptide extract of pineal gland. Its literature examines telomerase in cultured cells, melatonin rhythms in aged monkeys and older people, and lifespan and tumours in rodents and fruit flies. Nearly all of it comes from the developing group, most of it is cell and animal work, and the human studies are small. It is not approved as a medicine in Canada, the US, the EU or, as far as we could find, anywhere else.

A translucent brain in side view with the small pineal gland glowing at its centre
Illustration: the pineal gland, the source of the extract Epitalon was modelled on.

What is Epitalon made of?

Four amino acids, the smallest of the common research peptides on this site: alanine, glutamic acid, aspartic acid and glycine. Two of the four carry acidic side chains, so the molecule is small, water-soluble and negatively charged at neutral pH.

Its origin is the unusual part. Epithalamin is a mixture of short peptides extracted from bovine pineal tissue. A 2025 review by a Warsaw group describes Epitalon as synthesised from the amino-acid composition of that extract, before the tetrapeptide had been found in it (PMID 40141333). In 2017 the Khavinson group reported detecting AEDG among the tetrapeptides of the pineal polypeptide complex by mass spectrometry, and argued that the extract's effects come from this component (PMID 29124531). That second claim is the group's interpretation; the paper shows the peptide is present, not that it accounts for everything the extract does.

PropertyEpitalon
SequenceAla-Glu-Asp-Gly (AEDG)
Also calledEpithalon, Epithalone, AEDG peptide
CAS number (PubChem)307297-39-8
Molecular formula (PubChem)C14H22N4O9
Molecular weight (PubChem)About 390 g/mol
OriginSt Petersburg Institute of Bioregulation and Gerontology, Russia
Evidence stageMostly cell culture and animal; small human studies, nearly all from one group
Regulatory statusNot approved anywhere that we could find; no Health Canada, FDA or EMA authorisation

The two spellings describe the same molecule. "Epithalon" is the older transliteration and appears in many of the group's English papers; "Epitalon" is more common in recent ones.

How is Epitalon thought to work?

No receptor or specific molecular target has been identified. The proposals fall into three threads, all from cell or animal work and almost all from the same research network.

Telomerase. Khavinson and colleagues reported that adding Epitalon to telomerase-negative human fetal fibroblasts induced expression of the telomerase catalytic subunit, telomerase activity and telomere elongation (PMID 12937682). It is a three-page report in one cell type. Twenty-two years later an independent group at Brunel University London reported concentration-dependent telomere lengthening in normal epithelial cells and fibroblasts through TERT and telomerase, and lengthening in two breast cancer cell lines through a telomerase-independent route, alternative lengthening of telomeres (PMID 40908429). That is the most important independent paper on the compound, and its cancer-cell finding is why the telomerase story raises a question rather than settling one. The question is taken up in Epitalon and cancer risk.

Chromatin and gene expression. In cultured lymphocytes from people aged 76 to 80, the group reported that Epitalon activated ribosomal genes and loosened tightly packed heterochromatin (PMID 14647006). A later paper, with Italian co-authors, reported raised neuronal differentiation markers in human gingival stem cells and used computer modelling to propose that AEDG binds linker histones (PMID 32019204). The proposal that a four-residue peptide enters the nucleus and acts on chromatin is the group's central idea for all its short peptides. It rests on their own experiments and modelling, and has not been tested by an outside laboratory in the way the telomere result now has.

The pineal gland and melatonin. This was the original rationale. Its findings are described in the next section and in more depth in Epithalon, the pineal gland and melatonin.

The honest summary is that Epitalon has been reported to touch several systems, that one of those reports has been independently confirmed in cells, and that none has been tied to a defined target.

What has Epitalon been studied for?

AreaEvidence stageWhat exists
Telomeres and telomeraseCell cultureOne report from the developing group; one independent confirmation in normal and cancer cell lines
Melatonin and circadian rhythmMonkeys; small human studiesEvening melatonin and cortisol rhythm in aged rhesus monkeys; a Russian-language report in older people
Lifespan and ageing markersFruit flies; rodentsLifespan and biomarker studies, mostly small, one network
TumoursRodentsSpontaneous and induced tumour models with mixed results
RetinaRats; a small clinical reportRetinal degeneration in Campbell rats and patients with retinitis pigmentosa

Melatonin. In female rhesus monkeys, Goncharova, Khavinson and Lapin reported that Epitalon raised evening melatonin production in old animals and normalised the daily rhythm of cortisol (PMID 11550036; also PMID 11524632). A 2007 Russian-language paper by Korkushko and colleagues reported that epithalamin and Epitalon raised night-time melatonin in older people with low pineal output (PMID 17969590). The English abstract gives no group sizes, and the authors' conclusion that the preparations are fit for clinical use goes well beyond what a biomarker study can show.

Lifespan. In fruit flies, the group reported an 11 to 16 per cent longer adult lifespan when Epitalon was added to the larval medium (PMID 11087911). In a lifelong study in 54 female SHR mice per group, Anisimov and colleagues found no change in mean lifespan, no change in total spontaneous tumour incidence and less leukaemia, along with a longer lifespan among the last tenth of survivors and fewer chromosome aberrations in bone marrow (PMID 14501183). The unchanged mean is the headline that summaries tend to leave out.

Tumours. The rodent tumour work comes almost entirely from Anisimov's group at the Petrov Institute of Oncology. No study reported more tumours; the results otherwise vary by model and condition, and are set out study by study in Epitalon and cancer risk.

Retina. Khavinson and colleagues reported preserved retinal structure and function in Campbell rats with inherited retinal degeneration, and a positive clinical effect in 90 per cent of patients with retinitis pigmentosa (PMID 12195242). The abstract does not describe the clinical design in enough detail to judge it, and the result has not been repeated elsewhere.

A 2026 narrative review by Jain and colleagues, a US group with no stated interest in the compound, appraised this literature by design, sample size and replication. It concluded that human evidence is limited to small physiological or biomarker studies and an older controlled retinitis pigmentosa study, that no adequately powered randomised trial has established any therapeutic effect, and that pharmacokinetic and long-term safety data are inadequate (PMID 42884164). That is the fairest one-paragraph account available, and it is the one this page agrees with.

A search of ClinicalTrials.gov for Epitalon as an intervention, made for this page in November 2026, returned one registered study, an ageing-clock study enrolling by invitation with no results posted. None of the evidence above comes from a registered, prespecified trial.

Is Epitalon approved anywhere?

No. We found no authorisation from Health Canada, the FDA or the EMA, and no registration elsewhere comparable to Semax's in Russia. The Jain review notes regulatory uncertainties remaining after a 2026 FDA advisory review (PMID 42884164). In Belgium, analysts at the Scientific Institute of Public Health identified Epitalon in two illegal pharmaceutical preparations, sold with claims about cancer, old age and retinitis pigmentosa (PMID 25535022). Status in Canada can be checked in the Drug Product Database, and the general framework is set out in peptides and Canadian law.

What is Epitalon commonly confused with?

Epithalamin. The pineal extract Epitalon was modelled on. It is a mixture, not a single compound, and it has its own older literature, including human studies. Findings about epithalamin are often quoted as findings about Epitalon; the Jain review deliberately keeps them apart, and so should a reader.

Other Khavinson peptides. The same programme produced a family of short peptides, among them Vilon (Lys-Glu), Livagen and Cortagen, often tested side by side with Epitalon (PMID 15085253). They are different molecules. In one transgenic mouse study, Vilon went the opposite way to Epitalon on mammary tumours, as described in the cancer-risk article. Pinealon, the tripeptide Glu-Asp-Arg, comes from the same series despite a name that suggests the pineal gland; see what Pinealon is.

A proven longevity compound. The word "geroprotector" appears in paper titles. What exists is cell work, animal lifespan studies with mixed results and small human biomarker studies. No study has shown that it extends human life or slows ageing in people.

Supplied here for laboratory use: Epitalon. No certificate of analysis for this compound is published on this site yet. For laboratory research use only.

The findings above describe the compound in the animals, cells and people studied, not any laboratory reagent. Nothing here is medical, dosing, or therapeutic guidance.

Frequently asked questions

Is Epitalon the same as Epithalon? Yes. They are two transliterations of the same Russian name for the tetrapeptide Ala-Glu-Asp-Gly, also written AEDG. Epithalamin, with the extra syllable, is something else: the pineal extract the peptide was modelled on.

Does Epitalon lengthen telomeres? In cultured cells, two laboratories have reported that it does, the developing group in fetal fibroblasts and an independent UK group in normal epithelial cells and fibroblasts. The UK group also saw telomere lengthening in two breast cancer cell lines by a different route. No study has measured telomere length in human tissue after exposure.

Has Epitalon been tested in people? In small studies from the developing group, measuring melatonin and other biomarkers in older people, and in a clinical report in retinitis pigmentosa. None was a large randomised trial, and none has been repeated by another group. A 2026 independent review judged the compound biologically active but clinically unproven.

Why does almost all the research come from one group? Because Khavinson's group designed the compound and has studied it for more than 25 years, often publishing in Russian or in journals close to the group. That is the normal consequence of discovering a molecule, not evidence of error, but it means the findings share one set of methods and have had little outside checking. Why replication matters is covered in how to read a peptide study.

Is Epitalon legal in Canada? It has no Canadian authorisation as a drug. It is sold here as a laboratory research chemical, not for human use, and Health Canada states that peptides are generally regulated as prescription drugs.

Selected Research References

  1. Araj SK, Brzezik J, Mądra-Gackowska K, Szeleszczuk Ł. Overview of Epitalon: highly bioactive pineal tetrapeptide with promising properties. International Journal of Molecular Sciences. 2025;26(6):2691. pubmed.ncbi.nlm.nih.gov/40141333
  2. Khavinson VK, Kopylov AT, Vaskovsky BV, et al. Identification of peptide AEDG in the polypeptide complex of the pineal gland. Bulletin of Experimental Biology and Medicine. 2017;164(1):41-43. pubmed.ncbi.nlm.nih.gov/29124531
  3. Khavinson VKh, Bondarev IE, Butyugov AA. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bulletin of Experimental Biology and Medicine. 2003;135(6):590-592. pubmed.ncbi.nlm.nih.gov/12937682
  4. Al-Dulaimi S, Thomas R, Matta S, Roberts T. Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. Biogerontology. 2025;26(5):178. pubmed.ncbi.nlm.nih.gov/40908429
  5. Khavinson VKh, Lezhava TA, Monaselidze JR, et al. Peptide Epitalon activates chromatin at the old age. Neuro Endocrinology Letters. 2003;24(5):329-333. pubmed.ncbi.nlm.nih.gov/14647006
  6. Khavinson V, Diomede F, Mironova E, et al. AEDG peptide (Epitalon) stimulates gene expression and protein synthesis during neurogenesis: possible epigenetic mechanism. Molecules. 2020;25(3):609. pubmed.ncbi.nlm.nih.gov/32019204
  7. Goncharova ND, Khavinson VKh, Lapin BA. Regulatory effect of Epithalon on production of melatonin and cortisol in old monkeys. Bulletin of Experimental Biology and Medicine. 2001;131(4):394-396. pubmed.ncbi.nlm.nih.gov/11550036
  8. Khavinson V, Goncharova N, Lapin B. Synthetic tetrapeptide epitalon restores disturbed neuroendocrine regulation in senescent monkeys. Neuro Endocrinology Letters. 2001;22(4):251-254. pubmed.ncbi.nlm.nih.gov/11524632
  9. Korkushko OV, Lapin BA, Goncharova ND, et al. Normalizing effect of the pineal gland peptides on the daily melatonin rhythm in old monkeys and elderly people [in Russian]. Advances in Gerontology. 2007;20(1):74-85. pubmed.ncbi.nlm.nih.gov/17969590
  10. Khavinson VK, Izmaylov DM, Obukhova LK, Malinin VV. Effect of epitalon on the lifespan increase in Drosophila melanogaster. Mechanisms of Ageing and Development. 2000;120(1-3):141-149. pubmed.ncbi.nlm.nih.gov/11087911
  11. Anisimov VN, Khavinson VKh, Popovich IG, et al. Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR mice. Biogerontology. 2003;4(4):193-202. pubmed.ncbi.nlm.nih.gov/14501183
  12. Khavinson V, Razumovsky M, Trofimova S, et al. Pineal-regulating tetrapeptide epitalon improves eye retina condition in retinitis pigmentosa. Neuro Endocrinology Letters. 2002;23(4):365-368. pubmed.ncbi.nlm.nih.gov/12195242
  13. Jain A, Gallacher DM, Issa MA, et al. Epitalon and epithalamin: a narrative review of mechanistic, preclinical, and clinical evidence. International Journal of Molecular Sciences. 2026;27(19):8922. pubmed.ncbi.nlm.nih.gov/42884164
  14. Vanhee C, Moens G, Van Hoeck E, et al. Identification of the small research tetra peptide Epitalon, assumed to be a potential treatment for cancer, old age and retinitis pigmentosa in two illegal pharmaceutical preparations. Drug Testing and Analysis. 2015;7(3):259-264. pubmed.ncbi.nlm.nih.gov/25535022
  15. Khavinson VKh, Lezhava TA, Malinin VV. Effects of short peptides on lymphocyte chromatin in senile subjects. Bulletin of Experimental Biology and Medicine. 2004;137(1):78-81. pubmed.ncbi.nlm.nih.gov/15085253

All products sold by NovaEvum are for research and laboratory use only. They are not intended for human or animal consumption, diagnosis, treatment, cure, or prevention of any disease.